Viridian Therapeutics, Inc.
NASDAQ:VRDNBiotechnology
-$0.15 today
- Market cap
- $3.42B
- Beta
- 0.90
- P/E (TTM)
- -4.7
- EPS (TTM)
- -$3.53
Volume 1.49M
Average 2.86M
VRDN Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Viridian Therapeutics, Inc.NASDAQ: VRDN
Total Equity · Q2 FY2026 · quarter ended Jun 2026
Total equity rises 28.5% from a year ago
Total equity stood at $662.1M at the end of Q2 FY2026, up 28.5% from a year earlier and up 4.1% from the prior quarter. Over 3 fiscal years it compounded at +22.3% a year.
Context
- Total equity amounted to 60.3% of total assets at the end of Q2 FY2026, down 28.1 pp from a year earlier.
- Total equity increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +28.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 722.17M USD
- Year-over-year change
- +7.5%
- 4-year CAGR
- +40.1%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 722.17M | +7.5% |
| FY2024 | 2024-12-31 | 671.64M | +51.9% |
| FY2023 | 2023-12-31 | 442.02M | +11.9% |
| FY2022 | 2022-12-31 | 395.06M | +110.5% |
| FY2021 | 2021-12-31 | 187.72M | — |
Total Equity vs competitors
How VRDN compares with its peers on the latest reported figures
- VRDN's Jun 2026 total equity of $662.1M is the highest of the 4 companies compared; the peer median is $230.47M.
- Its year-over-year change of +28.5% is the 2nd highest of 4, against a peer median of +10.7%.
- Total equity amounts to 60.3% of total assets for VRDN, versus a peer median of 80.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $662.1M | +28.5% | +22.3% | 60.3% | |
| Mar 2026 | $581.57M | +118.7% | +164.5% | 79.4% | |
| Mar 2026 | $230.47M | -22.8% | +47.0% | 80.0% | |
| Mar 2026 | -$28.99M | +10.7% | — | 132.4% | |
| Peer median (excluding VRDN) | $230.47M | +10.7% | +105.7% | 80.0% | |
Competitors are the stored peer set for VRDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 42.3M | 155.58M | 102.83M | 99.59M | 212.38M |
| Short-term Investments | 154.67M | 268.97M | 374.54M | 617.99M | 662.27M |
| Net Receivables | 451K | 102K | 102K | 0 | 0 |
| Inventory | 0 | (6.62M) | 0 | 0 | 0 |
| Other Current Assets | 100K | 6.52M | 9.01M | 20.88M | 19.58M |
| Total Current Assets | 200.16M | 424.55M | 486.48M | 738.46M | 894.23M |
| Property, Plant & Equipment (Net) | 2.06M | 2.94M | 3.34M | 3.44M | 3.65M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.49M | 7.61M | 604K | 501K | 1.54M |
| Total Non-current Assets | 3.55M | 10.54M | 3.95M | 3.94M | 5.19M |
| Total Assets | 203.71M | 435.09M | 490.42M | 742.4M | 899.42M |
| Account Payables | 2.33M | 14.23M | 2.24M | 2.14M | 8.68M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 289K | 288K | 288K | 288K | 367K |
| Other Current Liabilities | 3.75M | 4.87M | 12.75M | 10.74M | 19.66M |
| Total Current Liabilities | 13.64M | 33.35M | 26.64M | 47.87M | 70.7M |
| Long-term Debt | 0 | 4.65M | 20.21M | 20.58M | 49.94M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 1.15M | 861K | 573K | 284K | 34.24M |
| Other Non-current Liabilities | 688K | 1.17M | 989K | 2.02M | 22.37M |
| Total Non-current Liabilities | 2.36M | 6.68M | 21.77M | 22.89M | 106.56M |
| Total Liabilities | 15.99M | 40.03M | 48.4M | 70.76M | 177.25M |
| Common Stock | 239K | 414K | 540K | 810K | 1.02M |
| Retained Earnings | (358.3M) | (488.17M) | (725.91M) | (995.86M) | (1.34B) |
| Accumulated OCI | (157K) | (390K) | 338K | (10K) | 447K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 187.72M | 395.06M | 442.02M | 671.64M | 722.17M |
| Total Debt | 1.04M | 5.26M | 21.05M | 21.1M | 50.69M |
| Net Debt | (41.26M) | (150.32M) | (81.78M) | (78.5M) | (161.69M) |
Viridian Therapeutics, Inc.
NASDAQ:VRDN
Intrinsic Alpha fair value
Locked
Current Price
$30.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.